anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Despite documented effectiveness in preventing several cancers, genital warts and safety of Human Papillomavirus (HPV) vaccine, immunization coverage among French adolescents remains far from the 80 % target. University health students (HS) in France may promote HPV vaccine through a national service (Service Sanitaire des Etudiants en Santé). We aimed to evaluate intentions to recommend the HPV vaccine to friends and relatives, to receive HPV vaccine, and to identify factors associated with these attitudes.
METHODS: We conducted a cross-sectional survey in five French Universities from October 2019 to February 2020, using a self-administered online questionnaire. We used bivariable and multivariable logistic regression models to identify determinants of behavior around HPV vaccine: (i) individual intention for vaccination, and (ii) vaccine recommendation to friends and relatives.
RESULTS: Among the 732 respondents (180 men, 552 women), 305 (41.7%) reported previous HPV vaccination (54.5 % among women), 504 (68.9%) would recommend the HPV vaccine to friends and relatives, 532 (72.7%) respondents would be vaccinated today if it was recommended for them. Intentions to recommend or to receive the HPV vaccine were less frequent in nursing students compared to medical and pharmacy students. After adjustment for demographical factors, HPV vaccine knowledge was associated with intention [aOR 1.30 (95%-confidence interval, 1.15-1.47)] and recommendation [1.26 (1.10-1.45)], respectively. Additionally, adjusting for knowledge about HPV infections, and confidence in vaccines in general was associated with vaccine intention [1.55, (1.30-1.84)] and recommendation [1.52 (1.24-1.86)]. HPV-vaccinated HS were more prone to recommend the HPV vaccine to friends and relatives [10.9 (6.6-17.9)].
CONCLUSION: A majority of HS would accept and/or recommend HPV vaccines. HS with greater knowledge about the HPV vaccine were more prone to recommend it. Strengthening knowledge about HPV and its vaccination is probably necessary before their Involvement in a HPV immunization program.
BACKGROUND: Etomidate has been advocated for anesthesia in older and critically ill patients because of its hemodynamic stability. Clinical studies have shown that dexmedetomidine has neuroprotective and anti-inflammatory properties and improves postoperative cognitive dysfunction in older patients. The present study was to evaluate the effects of the combination of etomidate and dexmedetomidine with different anaesthesia time on postoperative cognitive function in older patients.
METHODS: A total of 132 older patients undergoing ureteroscopic holmium laser lithotripsy were randomly divided into EN group and ED group equally. Patients whose surgery time was less than or equal to 1 h in each group were allocated to short-time surgery group (EN1 group and ED1 group), and whose surgery time was more than 1h were allocated to long-term surgery group (EN2 group and ED2 group). The primary outcome was the score of the Mini-Mental State Examination. The secondary outcomes were State-Trait Anxiety Inventory scores, Riker sedation agitation scores, Zung Self-Rating Depression Scale scores, the memory span for Arabic numerals, the plasma concentrations of S-100 calcium-binding protein B and neuron specific enolase, the time to spontaneous respiration, recovery, and extubation.
RESULTS: The MMSE scores at t2-3 were higher in ED1 and ED2 groups than in EN1 and EN2 groups (p<0.05). Compared with ED1 and ED2 groups, the ZSDS scores, the S-AI scores and the T-AI scores at t1-2 were higher in EN1 and EN2 groups (p<0.05), respectively. The recalled Arabic numbers at t1-3 were higher in ED2 group than in EN2 group (p<0.05). The plasma concentration of S-100β at t1-2 in EN1 group and t1-3 in EN2 group were higher than that in ED1 and ED2 groups (p<0.05), respectively. Compared with ED1 and ED2 groups, the plasma concentrations of NSE were higher at t1-3 in EN1 group and t1-4 in EN2 group (p<0.05), respectively.
CONCLUSION: The administration of dexmedetomidine could improve postoperative cognitive dysfunction, emergence agitation, depression and anxiety, attenuate the plasma concentrations of S-100β and NSE in older patients undergoing total intravenous anaesthesia with etomidate.
TRIAL REGISTRATION: Registration number: ChiCTR1800015421, Date: 29/03/2018.
The present invention provides a preparation method for a crystal form of PAC-1 . The crystal form A of PAC-1 provided in the present invention, by using CuKα radiation and an X-ray powder diffractogram represented with 2θ diffraction angles, shows characteristic peaks at 8.92 ± 0.2°, 17.14 ± 0.2°, 17.82 ± 0.2°, 18.90 ± 0.2°, 20.37 ± 0.2°, and 26.06 ± 0.2°. The crystal form A of PAC-1 of the present invention can be prepared by using an anti-solvent addition method, a suspension stirring method, a gas-liquid permeation method, a gas-solid permeation method, a slow cooling method, a slow volatilization method, a high polymer induction method, a humidity induction method or a grinding and recrystallization method. The crystal form A of PAC-1 of the present invention is suitable for industrial application in pharmacy. The crystal form has good solubility, and can improve the efficacy of a product. Moreover, the preparation process is simple and stable, has strong operability, and is suitable for industrial production. The crystal form has high stability.
The present invention relates to composite garlic juice and a preparation method thereof. The composite garlic juice is prepared by garlic, chicken intestines, bronze powder of chickens, brown sugar, cooked gingko powder, crystal sugar, red dates, tangerine peel, figs, common salt and vinegar. The preparation method has the steps that the chicken intestines and chicken gizzard are baked and are ground into powder, and then is stir-baked; the red dates and the figs are enucleated; the chicken intestines, the bronze powder of chickens, the brown sugar, the cooked gingko powder and the crystal sugar are mixed and arranged for a while; the red dates, the tangerine peel, welsh-onion stalk and the figs are arranged in the vinegar; dry matter is filtered out after 30 days of normal temperature and light protection; the preparation objects are mixed, the common salt and the garlic are added in the preparation objects, then, final encapsulation is carried out, and the product is obtained through 60 days of arrangement. The composite garlic juice of the present invention has the advantages good and sweet taste are portability. The recipe of the composite garlic juice is reasonable, so the effect of the garlic juice for treating dysentery is enhanced, and the dysentery stop speed is high. Patients get rid of the pain of the dysentery without any sequelae after drinking the composite garlic juice for 1 to 2 times. The composite garlic juice has no preservative, has long shelf life, can be stored more then 1 years when solids of the garlic, etc. are filtered off, and can be stored for more than 3 years when solids of the garlic, etc. are not filtered off.
A device for controlled dosed feeding of active substances into an operative medium comprises a hollow cylindrical compound casing (1) with at least one joint plane passing through the generatrix of the cylindrical casing (1). A partition is located within said plane dividing the casing (1) into sections (3) hermetically sealed in relation to the operative medium. Each section (3) has at least one means for connecting the casing (1) to the operative medium. The sections (3) of the casing (1), are interconnected by a torsion spring (4) whose axis is perpendicular to the longitudinal axis of the casing (1). The torsion spring (4) is mounted so as to provide for mutual rotation of the sections (3) of the casing (1), at the moment of its insertion into the operative medium, in the plane parallel to the longitudinal axis of the casing (1). The device is also provided with of least one stopper (5) made of a soluble material and mounted on the external surface of the casing (1).
A method is provided for encouraging patient compliance with a medicine regimen that includes interaction with the patient. The method includes the steps of providing a database which includes information regarding each patient. Information is supplied to the database by smart packages and other stakeholders. The information in the database is used to construct a patient report that may be viewed by the patient and others. Information in the patient report includes data on the patient's compliance, side effects of the medicine, expected results, interactions with other medicines, statements complimenting compliance, and warnings discouraging non-compliance. The patient report may be accessed by a common communication means such as the Internet.
A dendrobium officinale wine beverage with rice fragrance is disclosed. The beverage is prepared from following raw materials by weight: 15-17 parts of dendrobium officinale, 19-22 parts of glutinous rice wine, 5-8 parts of hawthorn leaf, 7-9 parts of watermelon peel, 10-13 parts of sugarcane juice, 7-8 parts of kumiss, 10-11 parts of crab apple, 6-7 parts of amaranth, 10-11 parts of common beet, 5-6 parts of lilac, 9-12 parts of red bean soup, 4-6 parts of konjac glucomannan, 6-8 parts of bitter cardamon, 1-2 parts of bitter orange, 4-6 parts of corn starch, 1-2 parts of asiatic bilberry leaf, 1-2 parts of rhinacanthus nasuta kurz, 3-4 parts of corn stigma, 7-10 parts of oat, 8-10 parts of nutrition additives and a proper amount of water. The beverage is sweet, fragrant and mellow. The raw materials of the beverage comprise the glutinous rice wine. The glutinous rice wine has functions of stimulating digestive gland secretion, helping digestion, and moistening skin. In addition, the beverage is rich in the bitter cardamon, the corn starch and a plurality of fruits, vegetables and bean products, rich in vitamins and trace elements, and rich in a plurality of amino acids, fatty acids, and the like. The beverage has functions of tonifying lung, calming heart, tonifying spleen, appetizing, and boosting human body immunity, and has high nutrition value and good drinking and healthcare effects.
Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.
Disclosed is an in vitro method for assessing whether a human patient has periodontitis. The method is based on the insight to determine biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of two or more of the proteins Matrix metalloproteinase-8 (MMP-8), Matrix metalloproteinase-9 (MMP-9), Pyruvate Kinase (PK) and S100 calcium-binding protein A8 (S100A8). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for absence of periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for periodontitis in said patient.
β-phenylethyl isothiocyanate (PEITC) is a phytochemical found in cruciferous vegetables with anti-cancer properties in vitro and in vivo. However, its pharmacokinetic profile in cancer survivors were unknown. A pharmacokinetic study was conducted in head and neck cancer survivors to evaluate the absorption and elimination profile of PEITC in the matrix of Nutri-jelly - a novel edible nutritious gel. Twelve head and neck cancer survivors consumed a serving of Nutri-jelly containing 20 mg PEITC. Plasma levels of PEITC at 0, 1, 2, 3, 4, 6, 8, 12 and 24 hours were specifically measured by ammonia derivatization and analyzed by LC-MS/MS. Non-compartmental pharmacokinetic analysis was performed. Pharmacokinetic parameters including Cmax, Tmax, half-life, clearance were analyzed.
PURPOSE:A pharmaceutical of doxorubicin salt, obtained by incorporating a dissolution assistant, e.g. a lower alkanoic acid or amino acid, in the doxorubicin salt which is ananthracycline based antitumor agent, and capable of dissolving even in a salt solution in a short time. CONSTITUTION:A least one of a lower alkanoic acid, lower alkanoic diacid, hydroxy lower alkanoic acid, amino acid, and urea-related substances as a dissolution assistant is incorporated in a doxorubicin salt expressed by the formula to give the titled pharmaceutical having improved solubility. A 2-4C hydroxy lower alkanoic acid, phenylalanine, serine, and urea etc. are preferred for the dissolution assistant, and the amount thereof to be used is preferably 1/10-3 times (W/W) of that of the doxorubicin salt. The dissolution time is remarkably reduced as compared with the case in the absence of the dissolution assistant.
This disclosure provides implantable devices with remote physiological monitoring capabilities. In particular, this disclosure relates to implantable devices with multi-spectral sensors that sense analyte from within a subject to provide clinically actionable data related to the subject's heath. For example, in preferred embodiments, the devices relate to ports with one or more multi-spectral sensors capable of remotely measuring symptoms of physiological distress via the multi-spectral sensors. In some embodiments, the ports are useful to deliver chemotherapy treatments and monitor patient health over the course of chemotherapy treatments. The multi-spectral sensors sense physical light properties modulated (e.g., reflected, absorbed, dispersed, scattered, etc.) by one or more analytes present in the body to allow for earlier detection of signs indicative of a health status.
Participants with recurrent GBM will receive RO7428731, IV in a dosing schedule determined in Part I. At the end of the Safety Run-in period, a decision will be made as to whether to open the Dose-Expansion Cohort Part IVA or open a second Safety Run-in Cohort at a lower dose.
The efficacy and safety of OMNITROPE were compared with another somatropin product approved for growth hormone deficiency (GHD) in pediatric patients. In sequential clinical trials involving a total of 89 GHD children, 44 patients received OMNITROPE for Injection (lyophilized powder) 5.8 mg/vial and 45 patients received the comparator somatropin product for 9 months. After 9 months of treatment patients who had received the comparator somatropin product were switched to OMNITROPE Cartridge (liquid) 5 mg/1.5 mL. After 15 months of treatment, all patients were switched to OMNITROPE Cartridge to collect long-term efficacy and safety data.

In both groups, somatropin was administered as a daily subcutaneous injection at a dose of 0.03 mg/kg. Similar effects on growth were observed between OMNITROPE for Injection and the comparator somatropin product during the initial 9 months of treatment.

The efficacy results after 9 months of treatment (OMNITROPE for Injection vs. the comparator somatropin product) and after 15 months (OMNITROPE Cartridge) are summarized in Table 5.
Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
Slow-tempo 60-80 beats per minute relaxing music. The intervention includes two one-hour music listening sessions, once in the morning and once in the evening for up to seven days, delivered through noise-canceling headphones and iPad.
Patients with bronchospastic disease (e.g., chronic bronchitis and emphysema) should, in general, not receive β‑blockers. COREG CR may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. It is prudent, if COREG CR is used, to use the smallest effective dose, so that inhibition of endogenous or exogenous β‑agonists is minimized.

In clinical trials of subjects with heart failure, subjects with bronchospastic disease were enrolled if they did not require oral or inhaled medication to treat their bronchospastic disease. In such patients, it is recommended that COREG CR be used with caution. The dosing recommendations should be followed closely and the dose should be lowered if any evidence of bronchospasm is observed during up‑titration.
Latinos suffer a greater disability burden from depression than whites due to low rates of quality depression care. Depression is common among Latinos in primary care settings and is also often chronic, recurring, and comorbid with chronic medical illness. Improving outcomes for both depression and chronic medical illness requires patients to become educated, active partners in managing their illnesses. Latinos desire education regarding general and mental health; have stigma-related concerns regarding mental health care; and prefer psychotherapy to medication. However, safety net primary care providers and clinics often prioritize improving medical outcomes and lack the resources for depression care, especially psychotherapy. There is an important public health need to develop a culturally tailored, low cost intervention that includes educational and psychotherapeutic elements, targets medical illness and depression, and destigmatizes depression care.

In response to patient, provider, and clinic preferences and resources for depression care, we developed but have not yet tested an innovative, theoretically-based group intervention, drawing upon two evidence-based interventions that improve self-efficacy: group cognitive behavioral therapy (CBT) for depression and group self-management for chronic medical illness. Professionally-led group CBT is effective for depression among ethnic minorities in primary care but is difficult to sustain. Among patients with chronic medical illness, lay-led group self-management programs educate and empower patients to engage in healthful behaviors and participate in their care. The groups improve self-efficacy, health-related behaviors, and outcomes; have been adapted for diverse conditions; and have been widely disseminated and sustained. However, standard self-management groups do not improve depression. We thus enhanced the Spanish-language Tomando Control de su Salud chronic disease self-management program by adding depression-related educational and skill-building content from group CBT.

We will pilot test and refine Cuerpo Sano, Mente Sana, our newly enhanced self-management program for depression and chronic medical illness. Following a framework for successful implementation of interventions, we will 1) evaluate intervention context and refine our intervention and implementation strategy; 2) conduct a randomized trial with 30 low-income Spanish-speaking patients with depressive disorder and chronic medical illness; 3) review pilot findings of feasibility, implementation, and potential sustainability with a multistakeholder panel and then revise our materials and procedures; 4) conduct a second trial with 30 additional patients; and 5) review additional pilot findings (including 3- and 6-month intervention effects on self-efficacy, self-care behaviors, and depression and health outcomes and interviews with clinic stakeholders) and finalize the intervention and implementation strategy. This study lays the groundwork for future comparative effectiveness studies of strategies to address depression among Latinos in safety net primary care.
FIELD: medicine. SUBSTANCE: method involves setting immune reaction of radioactive labeled isolate-specific antigen (GP) having molecular mass of 110-140 kD with antibodies (protein A-sepharose CL-4B) taken from virus-specific pig sera adsorbed on solid phase. Specific radioactivity of reaction products eluated from sorbent is measured by means of special counter. Antigen affinity is calculated from a formula.  3 H--glucose amine hydrochloride is used as metabolic GP marker. It is introduced into pig bone marrow cell culture infected with virus at a dose of 5-20 mcCu/ml. The GP is produced by solving infected cells in 1% triton X-100 in 0.02 M tris-HCl buffer at pH of 7.2-7.4. 22000 g ultracentrifuging and ion exchange chromatography on DEAE-cellulose is applied during 1 h with absorbed proteins of 0.125 M NaCl eluated on solving buffer. EFFECT: enhanced accuracy of method. 2 cl, 1 tbl
PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district of the University Zurich / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
Chronic obstructive pulmonary disease (COPD) is a highly prevalent chronic respiratory disease characterised by irreversible airways obstruction associated with chronic airways inflammation and remodelling, while the pathogenesis and the mechanistic differences between patients remain to be fully elucidated. We previously reported that alarmin cytokine IL-33 may contribute to the production of autoantibodies against respiratory epithelial cells. Here we expand the hypothesis that pulmonary autoimmune responses induced by airway microbiota also contribute to the progression of COPD. We focused on Edwardsiella tarda which we detected uniquely in the induced sputum of patients with acute exacerbations of COPD. Pernasal challenge of the airways of WT mice with supernatants of cultured E. tarda induced marked, elevated expression of IL-33 in the lung tissues. Immunisation of animals with supernatants of cultured E. tarda resulted in significantly elevated airways inflammation, the formation of tertiary lymphatic structures and significantly elevated proportions of T follicular helper T cells in the lung tissue and mediastinal lymph nodes. Interestingly, such challenge also induced production of IgG autoantibodies directed against lung tissue lysate, alveolar epithelial cell proteins and elastin fragment, while putrescine, one of metabolites generated by the bacterium, might play an important role in the autoantibody production. Furthermore, all of these effects were partly but significantly abrogated in mice with deletion of the IL-33 receptor ST2. Collectively, these data support the hypothesis that COPD is progressed at least partly by airways microbiota such as E. tarda initiating autoimmune attack of the airways epithelium mediated at least partly through the IL-33-ST2 axis.